Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians
Identifieur interne : 005135 ( Main/Curation ); précédent : 005134; suivant : 005136Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians
Auteurs : D. Milon [France] ; H. Allain ; J. M. Reymann ; G. Morel ; O. Sabouraud ; J. Van Den DriesscheSource :
- Fundamental and clinical pharmacology [ 0767-3981 ] ; 1990.
Descripteurs français
- Pascal (Inist)
- Heptaminol, Cardiotonique, Vasodilatateur coronarien, Voie parentérale, Homme, Parkinson maladie, Système nerveux pathologie, Toxicité, Bromocriptine, Antiparkinsonien, Hypotension artérielle, Hémodynamique, Appareil circulatoire pathologie, Chimiothérapie, Traitement, Stimulant dopaminergique, Récepteur dopaminergique D2, Renin.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Antiparkinson agent, Arterial hypotension, Blood Pressure (drug effects), Bromocriptine (adverse effects), Bromocryptine, Cardiotonic agent, Cardiovascular disease, Chemotherapy, Coronary vasodilator agent, D2 Dopamine receptor, Dopamine agonist, Double-Blind Method, Female, Heart Rate (drug effects), Hemodynamics, Heptaminol (adverse effects), Heptaminol (therapeutic use), Human, Humans, Hypotension, Orthostatic (chemically induced), Hypotension, Orthostatic (drug therapy), Injections, Intravenous, Male, Middle Aged, Nervous system diseases, Parenteral administration, Parkinson Disease (drug therapy), Parkinson disease, Renin, Renin (blood), Toxicity, Treatment.
- MESH :
- chemical , adverse effects : Bromocriptine, Heptaminol.
- chemical , blood : Renin.
- chemically induced : Hypotension, Orthostatic.
- drug effects : Blood Pressure, Heart Rate.
- drug therapy : Hypotension, Orthostatic, Parkinson Disease.
- chemical , therapeutic use : Heptaminol.
- Double-Blind Method, Female, Humans, Injections, Intravenous, Male, Middle Aged.
Abstract
Nineteen patients were included in the study: 7 displayed spontaneous orthostatic hypotension (OH), and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C03
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001448
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A51
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005C16
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001827
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001786
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001786
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000C38
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000C38
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000C38
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005A77
Links to Exploration step
Pascal:91-0171486Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0171486</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 91-0171486 INIST</idno>
<idno type="RBID">Pascal:91-0171486</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C03</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001448</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A51</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A51</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005C16</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:2096108</idno>
<idno type="wicri:Area/PubMed/Corpus">001827</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno>
<idno type="wicri:Area/PubMed/Curation">001786</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001786</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001786</idno>
<idno type="wicri:Area/Ncbi/Merge">000C38</idno>
<idno type="wicri:Area/Ncbi/Curation">000C38</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C38</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005A77</idno>
<idno type="wicri:Area/Main/Curation">005135</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</analytic>
<series><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Arterial hypotension</term>
<term>Blood Pressure (drug effects)</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocryptine</term>
<term>Cardiotonic agent</term>
<term>Cardiovascular disease</term>
<term>Chemotherapy</term>
<term>Coronary vasodilator agent</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Heart Rate (drug effects)</term>
<term>Hemodynamics</term>
<term>Heptaminol (adverse effects)</term>
<term>Heptaminol (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Hypotension, Orthostatic (chemically induced)</term>
<term>Hypotension, Orthostatic (drug therapy)</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parenteral administration</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Renin</term>
<term>Renin (blood)</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Renin</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypotension, Orthostatic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term>
<term>Heart Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypotension, Orthostatic</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Heptaminol</term>
<term>Cardiotonique</term>
<term>Vasodilatateur coronarien</term>
<term>Voie parentérale</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Toxicité</term>
<term>Bromocriptine</term>
<term>Antiparkinsonien</term>
<term>Hypotension artérielle</term>
<term>Hémodynamique</term>
<term>Appareil circulatoire pathologie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique D2</term>
<term>Renin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nineteen patients were included in the study: 7 displayed spontaneous orthostatic hypotension (OH), and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction</div>
</front>
</TEI>
<double idat="0767-3981:1990:Milon D:randomized:double:blind"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0171486</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 91-0171486 INIST</idno>
<idno type="RBID">Pascal:91-0171486</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C03</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001448</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A51</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A51</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005C16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D." last="Milon">D. Milon</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CHR Rennes, lab. pharmacologie exp. clin.</s1>
<s2>35043</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Région Bretagne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H." last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J. M." last="Reymann">J. M. Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G." last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O." last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J." last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</analytic>
<series><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Fundamental and clinical pharmacology</title>
<title level="j" type="abbreviated">Fundam. clin. pharmacol.</title>
<idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Arterial hypotension</term>
<term>Bromocryptine</term>
<term>Cardiotonic agent</term>
<term>Cardiovascular disease</term>
<term>Chemotherapy</term>
<term>Coronary vasodilator agent</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Hemodynamics</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parenteral administration</term>
<term>Parkinson disease</term>
<term>Renin</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Heptaminol</term>
<term>Cardiotonique</term>
<term>Vasodilatateur coronarien</term>
<term>Voie parentérale</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Toxicité</term>
<term>Bromocriptine</term>
<term>Antiparkinsonien</term>
<term>Hypotension artérielle</term>
<term>Hémodynamique</term>
<term>Appareil circulatoire pathologie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique D2</term>
<term>Renin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nineteen patients were included in the study: 7 displayed spontaneous orthostatic hypotension (OH), and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D" last="Milon">D. Milon</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes</wicri:regionArea>
<wicri:noRegion>CHR de Rennes</wicri:noRegion>
<wicri:noRegion>CHR de Rennes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G" last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O" last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J" last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2096108</idno>
<idno type="pmid">2096108</idno>
<idno type="wicri:Area/PubMed/Corpus">001827</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno>
<idno type="wicri:Area/PubMed/Curation">001786</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001786</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001786</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001786</idno>
<idno type="wicri:Area/Ncbi/Merge">000C38</idno>
<idno type="wicri:Area/Ncbi/Curation">000C38</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C38</idno>
<idno type="wicri:doubleKey">0767-3981:1990:Milon D:randomized:double:blind</idno>
<idno type="wicri:Area/Main/Merge">005A77</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatic hypotension in parkinsonians.</title>
<author><name sortKey="Milon, D" sort="Milon, D" uniqKey="Milon D" first="D" last="Milon">D. Milon</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, CHR de Rennes</wicri:regionArea>
<wicri:noRegion>CHR de Rennes</wicri:noRegion>
<wicri:noRegion>CHR de Rennes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name>
</author>
<author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name>
</author>
<author><name sortKey="Morel, G" sort="Morel, G" uniqKey="Morel G" first="G" last="Morel">G. Morel</name>
</author>
<author><name sortKey="Sabouraud, O" sort="Sabouraud, O" uniqKey="Sabouraud O" first="O" last="Sabouraud">O. Sabouraud</name>
</author>
<author><name sortKey="Van Den Driessche, J" sort="Van Den Driessche, J" uniqKey="Van Den Driessche J" first="J" last="Van Den Driessche">J. Van Den Driessche</name>
</author>
</analytic>
<series><title level="j">Fundamental & clinical pharmacology</title>
<idno type="ISSN">0767-3981</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Pressure (drug effects)</term>
<term>Bromocriptine (adverse effects)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Heart Rate (drug effects)</term>
<term>Heptaminol (adverse effects)</term>
<term>Heptaminol (therapeutic use)</term>
<term>Humans</term>
<term>Hypotension, Orthostatic (chemically induced)</term>
<term>Hypotension, Orthostatic (drug therapy)</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Renin (blood)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Renin</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypotension, Orthostatic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term>
<term>Heart Rate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypotension, Orthostatic</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Heptaminol</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Heptaminol is a molecule with experimental cardiovascular analeptic properties. In this double-blind vs placebo trial, the potency, so far unproven, of the injectable form of a 626 mg dose of heptaminol chlorhydrate on spontaneous or induced orthostatic hypotension (OH), was assessed. Nineteen patients were included in the study: 7 displayed spontaneous OH, and in the other 12 OH was induced by bromocriptine, as monitored 103 min/after an oral intake of 6.6 mg on average. Neither spontaneous nor induced OH were recorded in 32% of the Parkinsonian population registered, with no obvious distinctive characteristics. Potency tilt-trials, performed 15, 30 and 45 min after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the systolic blood pressure after 15 min (P less than 0.05). Clinical and biological tolerance was excellent. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of Parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The anti-hypotensive action of heptaminol does not seem to be related to any renal or even sympathetic interaction.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005135 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005135 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Curation |type= RBID |clé= Pascal:91-0171486 |texte= Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |